Schweiz
BioFire Diagnostics receives a de novo clearance by the FDA for the FilmArray® Meningitis/Encephalitis panel
04 November, 2015
FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform.continuing its extremely favorable business momentum
BioFire Diagnostics receives a de novo clearance by the FDA for the FilmArray® Meningitis/Encephalitis panel continuing its extremely favorable business momentum
09 Oktober, 2015
FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform
BioFire Receives FDA Clearance for the FilmArray® 2.0 System
26 Februar, 2015
New system delivers higher throughput, single database management and minimized footprint
Strategic alliance between bioMérieux and COPAN
14 Januar, 2015
BioFire Defense, a bioMérieux company, receives fast-track authorization of FilmArray® Ebola Test
27 Oktober, 2014
Marcy l’Etoile (France) - October 27, 2014 - BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E test™).